Want to see KR:207940 full AI Analyst Report?
SAMSUNG BIOLOGICS Co., Ltd. (207940) Income Statement
SAMSUNG BIOLOGICS Co., Ltd. Income Statement
Last quarter (Q2 2026), SAMSUNG BIOLOGICS Co., Ltd.'s total revenue was $1.32T, an increase of 2.40% from the same quarter last year. In Q2, SAMSUNG BIOLOGICS Co., Ltd.'s net income was $430.70B. See SAMSUNG BIOLOGICS Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 4.56T | $ 3.50T | $ 3.69T | $ 3.00T | $ 1.57T | |
| $ 2.48T | $ 1.68T | $ 1.77T | $ 1.44T | $ 784.97B | |
| $ 415.40B | $ 360.20B | $ 657.11B | $ 458.12B | $ 247.66B | |
| Depreciation and Amortization | $ 633.64B | $ 599.10B | $ 489.78B | $ 308.26B | $ 161.79B |
| $ 2.78T | $ 2.03T | $ 1.69T | $ 1.38T | $ 737.78B | |
| $ 2.07T | $ 1.32T | $ 1.11T | $ 983.63B | $ 537.31B | |
| $ 49.41B | $ 63.50B | $ 6.31B | $ 25.40B | $ 23.97B | |
| $ 2.12T | $ 1.38T | $ 1.12T | $ 1.01T | $ 561.28B | |
| $ 1.78T | $ 1.08T | $ 857.69B | $ 798.06B | $ 393.59B | |
| Per Share Metrics | |||||
| Basic EPS | $ 38588.00 | $ 23402.00 | $ 18528.00 | $ 17592.00 | $ 9050.12 |
| Diluted EPS | $ 38588.00 | $ 23402.00 | $ 18528.00 | $ 17576.00 | $ 9050.12 |
| Weighted Average Shares Outstanding | 46.24M | 46.29M | 46.29M | 45.36M | 43.49M |
| Weighted Average Shares Outstanding (Diluted) | 46.24M | 46.29M | 46.29M | 45.40M | 43.49M |
Currency in KRW
